R
Rui Wang
Researcher at Shanghai Jiao Tong University
Publications - 39
Citations - 636
Rui Wang is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 13, co-authored 37 publications receiving 438 citations. Previous affiliations of Rui Wang include Fudan University Shanghai Medical College.
Papers
More filters
Journal ArticleDOI
Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis
TL;DR: Adjuvant EG FR-TKI treatment may enhance disease-free survival and reduce the risk of distant metastasis in patients with EGFR-mutant NSCLC undergoing complete resection.
Journal ArticleDOI
Value of superb microvascular imaging ultrasonography in the diagnosis of carpal tunnel syndrome: Compared with color Doppler and power Doppler
TL;DR: Comprehensive consideration of SMI and CSA, CSA≥10.5 mm2, and/or SMI score ≥2 has the highest accuracy, significantly higher than that of CSA combination with CDUS or PDUS (68% and 69%, respectively, P <.05).
Journal ArticleDOI
Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma
Wen-Yang Jiang,Rui Wang,Xufeng Pan,Yuzhou Shen,Tianxiang Chen,Yunhai Yang,Jin-Cheng Shao,Lei Zhu,Baohui Han,Jun Yang,Heng Zhao +10 more
TL;DR: The prognosis of LELC was satisfactory, and commonly occurred in senior non-smoking women, and the patients with large tumor, accompanied with lymph nodes metastasis or at the advanced stage had the worst OS.
Journal ArticleDOI
Sublobar resection versus lobectomy in patients aged ≤35 years with stage IA non-small cell lung cancer: a SEER database analysis.
TL;DR: Considering sublobar resection better preserves lung function and has reduced overall morbidity, sublobby resection may be preferable for the treatment of young patients with stage IA NSCLC.
Journal ArticleDOI
Systemic Immune-Inflammation Index Predicts the Combined Clinical Outcome After Sequential Therapy With Abiraterone and Docetaxel for Metastatic Castration-Resistant Prostate Cancer Patients
Liancheng Fan,Rui Wang,Chenfei Chi,Wen Cai,Yong Zhang,Hongyang Qian,Xiaoguang Shao,Yanqing Wang,Fan Xu,Jiahua Pan,Yinjie Zhu,Xun Shangguan,Lixin Zhou,Baijun Dong,Wei Xue +14 more
TL;DR: To compare the antitumor effect of abiraterone followed by docetaxel‐prednisone or vice versa in metastatic castration‐resistant prostate cancer (mCRPC) patients, and explored factors that might predict combined PSA‐PFS, combined rPFS and OS.